Nikhil Lalwani Sells 33,481 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) CEO Nikhil Lalwani sold 33,481 shares of ANI Pharmaceuticals stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $57.99, for a total value of $1,941,563.19. Following the transaction, the chief executive officer now owns 370,378 shares of the company’s stock, valued at $21,478,220.22. This represents a 8.29 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

ANI Pharmaceuticals Stock Up 2.6 %

Shares of NASDAQ:ANIP opened at $59.39 on Friday. The firm has a market cap of $1.25 billion, a PE ratio of -107.98 and a beta of 0.71. The company has a fifty day simple moving average of $58.28 and a 200 day simple moving average of $60.75. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52. ANI Pharmaceuticals, Inc. has a 12-month low of $48.20 and a 12-month high of $70.81.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings data on Friday, November 8th. The specialty pharmaceutical company reported $1.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.09 by $0.25. ANI Pharmaceuticals had a positive return on equity of 15.87% and a negative net margin of 1.28%. The firm had revenue of $148.30 million for the quarter, compared to analysts’ expectations of $144.37 million. During the same period last year, the business posted $1.05 earnings per share. The firm’s revenue for the quarter was up 12.5% on a year-over-year basis. On average, equities research analysts anticipate that ANI Pharmaceuticals, Inc. will post 3.87 EPS for the current fiscal year.

Hedge Funds Weigh In On ANI Pharmaceuticals

A number of large investors have recently bought and sold shares of the business. SG Americas Securities LLC bought a new position in shares of ANI Pharmaceuticals during the first quarter valued at approximately $106,000. Vanguard Group Inc. increased its position in ANI Pharmaceuticals by 1.4% in the first quarter. Vanguard Group Inc. now owns 1,306,432 shares of the specialty pharmaceutical company’s stock worth $90,314,000 after buying an additional 17,460 shares during the period. O Shaughnessy Asset Management LLC bought a new stake in ANI Pharmaceuticals in the first quarter valued at $218,000. CANADA LIFE ASSURANCE Co boosted its holdings in shares of ANI Pharmaceuticals by 7.5% during the first quarter. CANADA LIFE ASSURANCE Co now owns 13,036 shares of the specialty pharmaceutical company’s stock valued at $900,000 after acquiring an additional 909 shares during the period. Finally, Price T Rowe Associates Inc. MD bought a new position in shares of ANI Pharmaceuticals during the first quarter worth about $289,000. Institutional investors own 76.05% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the company. Raymond James boosted their price target on ANI Pharmaceuticals from $81.00 to $83.00 and gave the stock an “outperform” rating in a report on Wednesday, September 18th. Truist Financial raised their target price on shares of ANI Pharmaceuticals from $60.00 to $62.00 and gave the stock a “hold” rating in a research report on Tuesday, October 22nd. Piper Sandler began coverage on ANI Pharmaceuticals in a research report on Friday, October 11th. They set an “overweight” rating and a $68.00 price target for the company. StockNews.com downgraded shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, September 7th. Finally, HC Wainwright reiterated a “buy” rating and issued a $94.00 target price on shares of ANI Pharmaceuticals in a research note on Monday, November 11th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $77.33.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.